PEGylated Proteins Market to Grow at CAGR of 11.17% through 2032 – Product Innovation, Product Differentiation, Mergers, Acquisitions, Partnerships and Strategic Alliances

The PEGylated proteins market size is anticipated to grow from USD 1.31 Billion in 2022 to USD 3.78 Billion in 10 years. The market ought to witness a positive growth rate owing to rising incidences of cancer across the globe. U.S., Canada and Mexico are the key countries contributing towards the regional market growth and development.

Newark, Dec. 18, 2023 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the global PEGylated Proteins market will grow from USD 1.31 Billion in 2022 to USD 3.78 Billion by 2032. With a long history and many well-established companies, Europe is another significant participant in the global industry. Europe has become a major player in the global market for PEGylated Proteins, with well-established biotechnology companies in the UK, Germany, and Switzerland. Europe holds a significant market share due to a cluster of biopharmaceutical businesses and research institutions in the regions at the forefront of PEGylation research and application. Europe’s collaborative research networks improve the region’s PEGylated Protein Creation capabilities. International partnerships between governments, businesses, and medical facilities encourage creativity and propel PEGylation technology forward. The European Union’s financing of cooperative research projects further enhances the region’s position in the international market.

Download Report Sample (230+ Pages PDF with Insights) at:

Key Insight of the PEGylated Proteins Market

Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.

During the forecast period, Asia-Pacific is expected to grow at the highest CAGR within the global PEGylated Proteins market. The Asia-Pacific region would significantly expand. Emerging nations such as China, India, Japan, and South Korea are prominent countries in the Asia Pacific region. The region’s governments are aggressively propelling the life sciences and biotechnology industry, resulting in the development of biopharmaceutical hubs. Thanks to this inflow of ingredients, Asia Pacific is becoming a major player in the worldwide PEGylated Protein Market. Asia-Pacific nations are increasing their capacity for biotechnology and molecular medicine research. PEGylation research is being actively pursued by academic institutions and research coordinators, which is helping the region increase its interest in PEGylation-related protein development. The region’s rise in the international market is further bolstered by the increase in highly qualified research experience. Growing attention is being paid to creating and marketing biosimilars and bio-generics in the Asia-Pacific region. Biologics that are PEGylated proteins are in line with this trend. The region’s concentration on offering affordable alternatives to biological medicines supports the expansion.

The interferons segment is expected to hold the second largest market share during the forecast period.

The protein type segment includes Colony-stimulating Factor (CSF), Interferons, Erythropoietin, Recombinant Factor VII and others. The interferons segment is expected to hold the second largest market share during the forecast period. A significant protein type in the PEGylated Proteins Market is interferons, a class of proteins with antiviral, antiproliferative, and immunomodulatory characteristics. PEGylated interferons are frequently used to treat chronic viral infections, such as hepatitis C. One example of this is PEGylated Interferon-alpha. Their capacity to lower dosing frequency by PEGylation and their effectiveness in controlling viral infections impact their market share.

The gastrointestinal disorders segment is expected to grow at the highest CAGR during the forecast period.

The application segment is bifurcated into cancer, autoimmune diseases, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorders and others. The gastrointestinal disorders segment is expected to grow at the highest CAGR during the forecast period. Within the PEGylated proteins market, gastrointеstinal problems comprise a broad category with applications ranging from focused treatments for particular ailments to enzyme replacement therapies. The frequency of gastrointеstinal illnesses, the demand for novel treatment strategies, and the ability of PEGylated proteins to target underlying disease mechanisms all impact the market. PEGylated proteins are used in the treatment of gastrointеstinal problems, such as pancreatic insufficiency, through the use of enzyme replacement therapy. Other enzymes, such as PEGylated lipases, aid in maintaining digestive processes and nutrient absorption.

The contract research organizations segment is expected to grow at the highest CAGR during the forecast period.

The end-user segment is bifurcated into pharmaceutical & biotechnology companies, contract research organizations and academic & research institutes. The contract research organizations segment is expected to grow at the highest CAGR during the forecast period. Contract Research Organizations (CROs) offer specialized services in clinical and clinical research, which is why they are important players in the global PEGylated Proteins market. They have contributed to large-scale clinical trials, pharmacokinetic interventions, and early-phase development. Through CROs, pharmaceutical and biotechnology businesses can partially outsource PEGylated protein production/manufacturing, resulting in cost savings and increased efficiency.

Impact of Covid-19 Pandemic

The pandemic caused weaknesses in the world’s supply chain, which affected the production of proteins that had been phosphorylated. Production was delayed, and shortages occurred due to lockdowns, transport restrictions, and interruptions in the raw material supply chains. Businesses experienced difficulties in ensuring a steady and timely supply of PEGylated medications, impacting patients who needed these treatments for various illnesses. The pandemic caused delays in clinical trial results, personnel constraints, lab closures, and disruptions to ongoing research and development in the PEGylated proteins market. The rate at which PEGylated protein innovation was occurring was also impacted by the redistribution of resources to COVID-19-related research. The re-evaluation of priorities by numerous pharmaceutical and biotechnological corporations may have impeded the advancement of phenolic treatments in developing countries.

Inquiry Before Buying:

Market Dynamics

Driver: Rising Prevalence of Chronic Diseases

Globally, the prevalence of chronic diseases like diabetes, heart problems, and autoimmunity disorders has significantly increased. This spike results from increased demand for efficient and focused treatments to treat these illnesses. Because of their improved pharmacokinetic characteristics, PEGylated proteins have become essential in treating chronic illnesses. As a result, as healthcare systems look for cutting-edge solutions, they contribute to market growth. Globally, the burden of chronic diseases has been rising for both developed and developing countries. The prevalence of these conditions has increased. Ageing populations, secondary lives, poor eating habits, environmental variables, and genetic predispositions are some factors driving this trend. Therefore, there is a need for advanced therapeutic approaches that can minimize side effects while managing chronic illnesses. This factor is boosting the market growth and development.

Restraint: Stringent Regulatory Standards

PEGylated products must undergo a rigorous regulatory approval process that requires effective evidence to prove their quality, safety, and efficacy. Protеins can have their pharmacokinetic and pharmacodynamic characteristics drastically changed by the covalent attachment of polyethylene glycol (PEG) polymers to the protein molecule, a process known as PEGylation. Consequentially, before authorizing PEGylated drugs for clinical use, regulatory bodies want substantial proof to assess the products’ safety and effectiveness. Standard evaluation criteria are difficult to establish because of the intricacy of PEGylation and the variety of PEGylated proteins. The approval process is inconsistent because of differences in regulatory standards between nations and regions. The absence of harmonization could affect patient care and therapeutic developments by delaying the market entry of PEGylated pharmaceuticals.

Opportunity: Increasing Patient Awareness and Demand for Biologics

The increasing patient awareness about biologics is anticipated to provide lucrative growth opportunities in the upcoming years. A class of medications known as biologics, or biologic therapies, are derived from living things or parts of them. These teachers’ focused approach and promise for personalized medicine have drawn attention. Through a variety of sources, including patient advocacy organizations, industry resources, and healthcare professionals, patients are becoming more knowledgeable about cutting-edge therapeutic alternatives, including biologics. The availability of data regarding the advantages and effectiveness of biological therapy for various medical diseases is causing this unprecedented awareness. Patients are seeking more individualized therapies, which is driving up demand for targeted and targeted medication. Because biologic therapies can target specific pathways or molecular targets, they align with this requirement. Unlike conventional medications frequently prescribed for larger patient populations, biologics allow more specific and customized treatment techniques.

Browse the full report with Table of Contents and List of Figures:

Some of the major players operating in the PEGylated Proteins market are:

• Thermo Fisher Scientific, Inc.
• Abcam plc.
• Enzon Pharmaceuticals, Inc.
• Merck KGaA
• Celares GmbH
• Profacgen
• Creative PEGworks
• NOF America Corp.
• Aurigene Pharmaceutical Services Ltd.
• Laysan Bio, Inc.

Key Segments Cover in the Market:

By Protein Type:

• Colony-stimulating Factor
• Interferons
• Erythropoietin
• Recombinant Factor VII
• Others

By Application:

• Cancer
• Autoimmune Diseases
• Hepatitis
• Multiple Sclerosis
• Hemophilia
• Gastrointestinal Disorders
• Others

By End-user:

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutes

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, the U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Inquire for Customized Data:

About the report:

The market is analyzed based on value (USD Billion). All the segments have been analyzed worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyzes driving factors, opportunities, restraints, and challenges to gain critical market insight. The study includes porter’s five forces model, attractiveness analysis, product analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channel analysis.

About The Brainy Insights:

The Brainy Insights is a market research company that provides actionable insights through data analytics to companies to improve their business acumen. They have a robust forecasting and estimation model to meet the client’s objectives of high-quality output within a short period. They provide both customized (client-specific) and syndicate reports. Their repository of syndicate reports is diverse across all the categories and sub-categories across domains. Their customized solutions meet the client’s requirements whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D
Head of Business Development
Phone: +1-315-215-1633

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy